Union Minister Dr Jitendra Singh Announces India's Leap to Global Leader in Precision Medicine, Multi‑Omics & Biomanufacturing

<h2>Overview</h2> <p>At the <span class="key-term" data-definition="Multi‑omics – integrated analysis of genomics, transcriptomics and proteomics to understand disease mechanisms; increasingly important in biotechnology and health policy (GS3: Science & Technology)">Multi‑Omics Summit 2026</span>, Union Minister of State (Independent Charge) for Science & Technology, <strong>Dr Jitendra Singh</strong> declared that India is moving from a phase of seeking advanced treatment abroad to becoming a global destination for precision medicine, biomanufacturing and medical innovation.</p> <h3>Key Developments</h3> <ul> <li>Launch of the comprehensive <span class="key-term" data-definition="BioE3 policy – a government framework that leverages biotechnology for economy, environment and employment, aimed at accelerating innovation and bio‑economy growth (GS3: Economy)">BioE3 policy</span>.</li> <li>Allocation of <strong>₹10,000 crore</strong> under the <span class="key-term" data-definition="Biopharma Shakti scheme – a funding programme to set up biomanufacturing hubs, bio‑foundries and advanced research infrastructure, boosting domestic production of biologics (GS3: Economy)">Biopharma Shakti scheme</span>.</li> <li>Growth of biotech ecosystem to **over 11,000 startups**, up from a few dozen a decade ago.</li> <li>Progress in large‑scale genomics: completion of ~10,000 genome sequences under the <span class="key-term" data-definition="Genome India Project – a national initiative to sequence Indian genomes for research on disease patterns and personalised therapies (GS3: Science & Technology)">Genome India Project</span>, with the upcoming <span class="key-term" data-definition="Phenome India – a planned initiative to map phenotypic traits across the Indian population, complementing genomic data (GS3: Science & Technology)">Phenome India</span> initiative.</li> <li>Integration of <span class="key-term" data-definition="Precision medicine – medical approach that tailors prevention, diagnosis and treatment to individual genetic, environmental and lifestyle factors (GS3: Science & Technology)">precision medicine</span> with AI, traditional systems like Ayurveda, and modern biotech.</li> <li>Opening of the nuclear sector to private participation, fostering innovation in nuclear medicine.</li> </ul> <h3>Important Facts</h3> <p>The Ministry of <span class="key-term" data-definition="AYUSH – a dedicated ministry for Ayurveda, Yoga, Unani, Siddha and Homeopathy, promoting integration of traditional knowledge with modern science (GS2: Polity)">AYUSH</span> and expanded biotechnology platforms have enabled hybrid healthcare models. Recent breakthroughs include gene‑based therapies for sickle‑cell disease and hemophilia, and nuclear‑medicine treatments for acute lymphoblastic leukaemia at Tata Memorial Centre.</p> <p>India’s genetically diverse population provides a unique advantage for multi‑omics research, allowing the identification of disease patterns across varied ethnic groups.</p> <h3>UPSC Relevance</h3> <ul> <li>Understanding the <span class="key-term" data-definition="Bioeconomy – economic activity derived from scientific and technological applications of biological resources, crucial for sustainable development (GS3: Economy)">bio‑economy</span> and its policy framework aligns with GS‑3 topics on science‑technology and economic growth.</li> <li>Knowledge of the <span class="key-term" data-definition="Biopharma Shakti scheme – a major fiscal push to develop domestic biomanufacturing capacity, relevant for questions on industrial policy and self‑reliance (GS3: Economy)">Biopharma Shakti</span> helps answer questions on Make‑in‑India and health‑sector self‑reliance.</li> <li>Insights into the integration of traditional systems (AYUSH) with modern biotech are pertinent for GS‑2 (Polity) and GS‑4 (Ethics) discussions on cultural heritage and innovation.</li> <li>Multi‑omics and precision medicine illustrate the role of AI and data‑driven health governance, a recurring theme in GS‑3 and GS‑4.</li> </ul> <h3>Way Forward</h3> <p>To sustain momentum, the government must:</p> <ul> <li>Strengthen public‑private partnerships for research and manufacturing.</li> <li>Ensure robust data‑privacy and ethical frameworks for genomic databases.</li> <li>Scale up skill development programmes to create a skilled biotech workforce.</li> <li>Promote export‑oriented biopharma clusters to capture global market share.</li> </ul> <p>With continued policy support and a vibrant research ecosystem, India can lead the next wave of global healthcare innovation.</p>